Isotechnika's Canadian Phase 3 psoriasis trial published
Isotechnika Inc. announced that The Lancet will publish an article titled "Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study". The article discusses the relationship between drug dose and clinical response demonstrated in the Canadian Phase 3 trial, suggesting that patients can be more accurately dosed to achieve desired response compared with currently marketed calcineurin inhibitors. An editorial will also be included on the use of voclosporin (ISA247) as a treatment for patients suffering from moderate to severe psoriasis.
"The Lancet is one of the world's leading peer-reviewed medical journals and we are extremely honoured that this prestigious journal would acknowledge the work we are doing with voclosporin in the field of psoriasis," stated Dr. Robert Foster, Isotechnika Chairman & CEO. "To that end, we would also like to take this opportunity to thank all of the patients, investigators and study coordinators who participated in the trial. Without them we would not be able to advance voclosporin through the clinical trial process."
Other news from the department research and development
